Crystalgenomics, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Nov 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 17, 2027The maintenance fee for Oral pharmacological composition including 5-{4-(amino sulfonyl)phenyl}-2,2-dimethyl-4-(3-fluorophenyl)-3(2H)-furanone having crystalline structure with excellent stability (US 10,413,520) comes due Mar 17, 2027. Unpaid by Sep 17, 2027, it lapses early.
- 1 fee due Sep 30, 2027The maintenance fee for 2,3-dihydro-isoindole-1-one derivative as BTK kinase suppressant, and pharmaceutical composition including same (US 10,604,508) comes due Sep 30, 2027. Unpaid by Mar 31, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 8 of 8
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,053,435 | Naphthalenyloxypropenyl Derivatives Having Inhibitory Activity Against Histone Deacetylase and Pharmaceutical Composition Comprising the Same In force · High confidence | In force | High confidence | |
| US 7,973,060 | Fab I inhibitor and process for preparing same In force · From the USPTO record | In force | From the USPTO record | |
| US 9,758,508 | 2,3-dihydro-isoindole-1-on derivative as BTK kinase suppressant, and pharmaceutical composition including same In force · From the USPTO record | In force | From the USPTO record | |
| US 10,604,508 | 2,3-dihydro-isoindole-1-one derivative as BTK kinase suppressant, and pharmaceutical composition including same In force · From the USPTO record | In force | From the USPTO record | |
| US 11,230,539 | 2,3-dihydro-isoindole-1-one derivative as BTK kinase suppressant, and pharmaceutical composition including same In force · From the USPTO record | In force | From the USPTO record | |
| US 10,413,520 | Oral pharmacological composition including 5-{4-(amino sulfonyl)phenyl}-2,2-dimethyl-4-(3-fluorophenyl)-3(2H)-furanone having crystalline structure with excellent stability In force · From the USPTO record | In force | From the USPTO record | |
| US 11,655,207 | Pharmaceutically Acceptable Salt of Alkylcarbamoyl Naphthalenyloxy Octenoylhydroxyamide or of Derivative Thereof and Method for Preparing Same In force · High confidence | In force | High confidence | |
| US 11,602,517 | Pharmaceutical Composition, Comprising Polmacoxib and Pregabalin, for Treatment of Pain In force · High confidence | In force | High confidence |
Also on record, not counted in the 8: 2 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 1 abandoned · 13 no status recorded